Evaluating only BioSpain Therapeutics’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
FOUNDING
FUNDING
MILESTONE
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
BioSpain Therapeutics developed treatments for rare neurological disorders from its Barcelona lab. Despite promising preclinical results and a €9.5M seed round, the company exhausted capital in Phase II trials without landing the pharma partnership needed to fund Phase III. European biotech investors proved risk-averse compared to US peers, and the company dissolved quietly as patents neared expiration.
Lesson
“Rare disease biotechs in Europe need transatlantic partnerships from day one — local capital cannot fund Phase II and beyond alone.”
Failure anatomy
Collapse type
Slow Death
🐌 LOW
Hype cycle
Trough
Moat type
IP
Fatal mistake
Failed to secure pharma partnership before Phase II trials consumed remaining runway